OR WAIT null SECS
PHILADELPHIA – September 8, 2017 – ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, announced it has acquired Biomedical Systems, a well-recognized provider of reliable imaging, as well as cardiac safety and respiratory data collection solutions. Financial terms of the transaction were not disclosed.
Coupled with its recent addition of imaging technology invented by the Cleveland Clinic, the acquisition of Biomedical Systems enables ERT to further expand its ability to reduce customer risk and uncertainty when imaging, cardiac safety and respiratory data collection are required. In particular, the acquisition positions ERT to better meet the significant demand for imaging in clinical trials, which is being driven from regulators’ increasing requests that imaging data be included in submissions.
“This acquisition complements our current capabilities and enables us to quickly scale and fully support our customers’ needs for consistent, accurate and verifiable imaging data without adding administrative burden to investigative sites,” said James Corrigan, President and CEO of ERT. “We are delighted to welcome Biomedical Systems to the ERT team, and look forward to a seamless transition and continuing to deliver market-leading offerings that solve our clients’ most complex challenges.”
“By merging ERT’s high tech imaging capabilities and Biomedical Systems’ expertise from supporting over 500 imaging trials, the combined organization delivers the optimal solution to overcome complex challenges in clinical research,” said Tim Barrett, CEO of Biomedical Systems. “We’re excited to apply our combined 70 years of experience to further help clinical trial sponsors and CROs accelerate clinical development and bring new medicines to market more efficiently.”
For more information on ERT, visit ert.com.
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With more than 40 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.
Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. Since 2014, more than half of all FDA drug approvals came from ERT-supported studies. Pharma companies, Biotechs and CROs have relied on ERT solutions in 9,500+ studies spanning three million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly – and with confidence. For more information, go to ert.com or follow us on LinkedIn and Twitter.
About Biomedical Systems
Biomedical Systems is a premier global provider of centralized diagnostic services.
Founded in 1975, Biomedical Systems has grown to be a leading clinical trial provider to pharmaceutical, medical device, biotech, and CROs. Its comprehensive clinical trial solutions include cardiac safety, pulmonary function, imaging, eCOA, and scientific affairs.
Biomedical Systems’ corporate headquarters is located in St. Louis, Missouri. European headquarters is located in Brussels, Belgium with supporting offices in Japan and India, which are able to resupply equipment and materials to challenging areas around the world in a timely, cost-effective manner. Its global staff speaks 21 languages, facilitating communication with international sponsors and sites delivering better quality data. With strategically located offices spanning the globe, Biomedical Systems has managed thousands of clinical trials in over 95 countries and can offer services and support 24 hours a day.
For additional information visit www.biomedsys.com.